Free fatty acids are involved in the inverse relationship between hormone-sensitive lipase (HSL) activity and expression in adipose tissue after high-fat feeding or β3-adrenergic stimulation

被引:26
作者
Berraondo, B [1 ]
Martínez, JA [1 ]
机构
[1] Univ Navarra, Dept Physiol & Nutr, Pamplona 31008, Navarra, Spain
来源
OBESITY RESEARCH | 2000年 / 8卷 / 03期
关键词
beta(3)-adrenergic agonists; cafeteria diet; fatty acids; hormone-sensitive lipase; obesity;
D O I
10.1038/oby.2000.30
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The hormone-sensitive lipase (HSL) is the rate-limiting enzyme in adipose tissue lipolysis. The aim of this experimental trial was to study the effects of a beta(3)-adrenergic agonist (Trecadrine) on plasma fatty acids, adipocyte HSL activity, and gene expression in control and cafeteria-induced obese animals. Research Methods and Procedures: Control and cafeteria-fed rats were treated with a placebo or Trecadrine during 35 days. Plasma fatty acids were measured by an enzymatic method, whereas HSL activity was assessed by using labeled triolein as substrate. Finally, HSL gene expression from white adipose tissue (WAT) was determined using a reverse transcription-polymerase chain reaction method. Results: Trecadrine administration reduced plasma fatty acids and HSL mRNA levels in abdominal WAT, whereas HSL activity was significantly higher in the Trecadrine-treated obese rats than in the obese nontreated rats. Also, abdominal WAT HSL activity significantly increased, whereas WAT HSL gene expression fell in control rats treated with beta(3)-adrenergic agonist as compared with control untreated animals. Discussion: In situations of fat accumulation (high-fat feeding) or lipid mobilization (beta(3)-adrenergic stimulation), changes in HSL activity and HSL gene expression seem to follow a trend related to plasma fatty acids levels, as indicated by the positive correlation (r = 0.39, p < 0.05) between HSL mRNA levels and plasma fatty acids, and the negative correlation (r = -0.38, p < 0.05) between plasma fatty acids and HSL activity. Furthermore, a highly negative correlation (r = -0.59, p < 0.001) between HSL activity and HSL mRNA expression was found, in which plasma-free fatty acids are apparently involved.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 35 条
[1]  
ARNER P, 1996, DIABETES REV, V4, P450
[2]   Potential anti-diabetic applications of a new molecule with affinity for beta(3)-adrenoceptors [J].
Barrionuevo, M ;
Milagro, FI ;
Cenarruzabeitia, E ;
Martinez, JA .
LIFE SCIENCES, 1996, 59 (11) :PL141-PL146
[3]  
Berraondo B, 1997, Eat Weight Disord, V2, P130
[4]   EFFECT OF THE BETA-ADRENOCEPTOR AGONIST BRL-35135 ON DEVELOPMENT OF OBESITY IN SUCKLING ZUCKER (FA/FA) RATS [J].
CHARON, C ;
DUPUY, F ;
MARIE, VV ;
BAZIN, R .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (06) :E1039-E1045
[5]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[6]   Effects of trecadrine, a beta(3)-adrenergic agonist, on intestinal absorption of D-galactose and disaccharidase activities in three physiopathological models [J].
DiezSampedro, A ;
Milagro, FI ;
Berraondo, B ;
Zulet, MA ;
Martinez, JA ;
Barber, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (09) :873-877
[7]   Are increased plasma nonesterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? [J].
Frayn, KN ;
Williams, CM ;
Arner, P .
CLINICAL SCIENCE, 1996, 90 (04) :243-253
[8]   COORDINATED REGULATION OF HORMONE-SENSITIVE LIPASE AND LIPOPROTEIN-LIPASE IN HUMAN ADIPOSE-TISSUE IN-VIVO - IMPLICATIONS FOR THE CONTROL OF FAT STORAGE AND FAT MOBILIZATION [J].
FRAYN, KN ;
COPPACK, SW ;
FIELDING, BA ;
HUMPHREYS, SM .
ADVANCES IN ENZYME REGULATION, VOL 35, 1995, 35 :163-178
[9]   Characterization of the promoter of human adipocyte hormone-sensitive lipase [J].
Grober, J ;
Laurell, H ;
Blaise, R ;
Fabry, B ;
Schaak, S ;
Holm, C ;
Langin, D .
BIOCHEMICAL JOURNAL, 1997, 328 :453-461
[10]   Improvement of metabolic disorders and visceral fat obesity by the beta(3)-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents [J].
Hashimoto, K ;
Nagao, Y ;
Ida, K .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (10) :1529-1535